EUVIMEDEUVIMED entdecken
Open Access

Assessing causality in deprescribing studies: A focus on adverse drug events and adverse drug withdrawal events

Xiaojuan Li iD, Elizabeth A Bayliss, M Alan Brookhart, Matthew L Maciejewski

Journal of the American Geriatrics Society · 2025-03 · 73 (3) · 697-706

DOI: 10.1111/jgs.19241 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of the American Geriatrics Society, online erschienen am 24.10.2024. Verfasst von Xiaojuan Li und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care Institute, Boston, Massachusetts, USA. Hauptthemen laut MEDLINE: Deprescriptions, Drug-Related Side Effects and Adverse Reactions, Substance Withdrawal Syndrome. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIA NIH HHS, VA, Center for Integrated Healthcare, U.S. Department of Veterans Affairs.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Generating real‐world evidence about the effect of medication discontinuation or dose reduction on outcomes, such as reduction of adverse drug effects (ADE; intended benefit) and occurrence of adverse drug withdrawal events (ADWE; unintended harm), is crucial to informing deprescribing decisions. Determining the causal effects of deprescribing is difficult for many reasons, including lack of randomization in real‐world study designs and other design and measurement issues that pose threats to internal validity. The inherent challenge is how to identify the effects, both intended benefits and unintended harms, of a new medication stoppage or reduction when implemented in patients with many potential clinical and social risks that may influence the likelihood of deprescribing as well as outcomes. We discuss methodological issues of estimating the effect of medication discontinuation or reduction on risk of ADEs and ADWEs considering: (1) sampling study populations of sufficient size with the potential to demonstrate clinically meaningful and quantifiable outcomes, (2) accurate and appropriately timed measurement of covariates, outcomes, and discontinuation, and (3) statistical approaches to managing confounding and other biases inherent in long‐term medication use by individuals with multiple morbidities. Designing rigorous deprescribing studies that address internal validity threats will support evidence generation by improving the ability to assess benefits and harms when the exposure of interest is the absence of a medication. Iterative learnings about data quality, variable definition, variable measurement, and exposure‐outcome associations will inform strategies to improve the causal inferences possible in real‐world deprescribing studies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DeprescriptionsDrug-Related Side Effects and Adverse ReactionsSubstance Withdrawal SyndromeHumansResearch DesignCausality

Stichwörter der Autor:innen

adverse drug effectsadverse drug withdrawal effectsdeprescribingmedication management

Autor:innen und Institutionen

  • Department of Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care Institute, Boston, Massachusetts, USA.
  • Institute for Health Research, Kaiser Permanente Colorado, Aurora, Colorado, USA.
  • Department of Family Medicine, University of Colorado School of Medicine, Aurora, Colorado, USA.
  • Department of Population Health Sciences, Duke University, Durham, North Carolina, USA.
  • Center of Innovation to Accelerate Discovery & Practice Transformation, Durham VA Medical Center, Durham, North Carolina, USA.
  • Division of General Internal Medicine, Department of Medicine, Duke University, Durham, North Carolina, USA.

ORCID-Profile: Xiaojuan Li

Förderung

  • NIA NIH HHS
  • VA
  • Center for Integrated Healthcare, U.S. Department of Veterans Affairs
  • National Institute on Aging

Zitieren

APA

Li, X., Bayliss, E. A., Brookhart, M. A., & Maciejewski, M. L. (2025). Assessing causality in deprescribing studies: A focus on adverse drug events and adverse drug withdrawal events. Journal of the American Geriatrics Society, 73(3), 697-706. https://doi.org/10.1111/jgs.19241

Vancouver

Li X, Bayliss EA, Brookhart MA, Maciejewski ML. Assessing causality in deprescribing studies: A focus on adverse drug events and adverse drug withdrawal events. Journal of the American Geriatrics Society. 2025;73(3):697-706. doi:10.1111/jgs.19241

BibTeX
@article{Li2025,
  author = {Li, Xiaojuan and Bayliss, Elizabeth A and Brookhart, M Alan and Maciejewski, Matthew L},
  title = {Assessing causality in deprescribing studies: A focus on adverse drug events and adverse drug withdrawal events},
  journal = {Journal of the American Geriatrics Society},
  year = {2025},
  volume = {73},
  number = {3},
  pages = {697--706},
  doi = {10.1111/jgs.19241}
}
Kostenlos starten →